BioWorld Asia

Feb. 19, 2003

Oxford GlycoSciences Considers Interest From Celltech, Others

LONDON - Celltech Group plc has refused to comment on reports that it is preparing to make a cash bid for Oxford GlycoSciences plc, undermining the agreed-to all-share takeover offer made by Cambridge Antibody Technology Group plc on Jan. 23. (BioWorld International) Read More

Diatos Raises EUR6.5M Privately To Fund Delivery Technology

Work On Lymphocyte Infection Could Have Implications In HIV

Dolly The Cloned Sheep Opened Research Doors In Biotechnology

Biotech Companies Included In New German Stock Index

SIRTeX Officials Welcome Idea Of $161M Acquisition By Cephalon

Active Biotech Seeks $26.5M In Discounted Rights Offering

Investment Rules Delay First Closing Of New Nordic Fund

Wilex Expands uPA Program Through Deal With San Raffaele

Fees For EMEA Registration Increasing For The First Time

Cerep, Sanofi-Synthélabo Renew Drug Discovery Collaboration

Other News To Note

Correction

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 17, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

European Commission floats multiple fixes for MDR, IVDR

BioWorld MedTech

The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...

ATNM-400 radioconjugate shows efficacy in resistant breast cancer

BioWorld Science

Although hormone receptor-positive (HR+) breast cancer accounts for over 70% of cases, 20%-30% of patients still experience relapse despite endocrine therapies...